Microarray Technology Aids in Breast Cancer Prognosis

Microarray Technology Aids in Breast Cancer Prognosis


A cutting-edge prognostic tool called MammaPrint, developed by Agendia, a laboratory located in The Netherlands, uses molecular technology to predict whether breast cancer will metastasize, helping clinicians make more accurate management decisions for their patients.

"Clearance of MammaPrint marks a step forward in the initiative to bring molecular-based medicine into current practice," FDA commissioner Andrew C. von Eschenbach, MD, noted in a public statement following MammaPrint's FDA approval.

Cancer Care & Economics (CC&E) recently spoke with Ren Bernards, PHD, chief scientific officer of the team that developed this significant new test.

CC&E: Microarray analysis in itself is not new—what scientific application was MammaPrint created to address? What makes it a first-of-its-kind test?

DR. BERNARDS: Agendia decided to use microarray technology instead of other techniques like reverse transcription polymerase chain reaction (RT-PCR) because it allows the whole genome to be analyzed at once, identifying the most relevant genes to develop a signature. We succeeded in finding the set of genes that was proven to be significant in the prognosis of breast cancer tumor recurrence.

CC&E: What molecular activity does MammaPrint identify as a prognostic factor?

DR. BERNARDS: The 70 genes analyzed in the MammaPrint breast cancer test are genes involved in cell cycle, invasion, metastasis, and angiogenesis.


Loading comments...
Please Wait 20 seconds or click here to close